<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="253">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285050</url>
  </required_header>
  <id_info>
    <org_study_id>NA00040361</org_study_id>
    <secondary_id>R01DA013806</secondary_id>
    <nct_id>NCT01285050</nct_id>
  </id_info>
  <brief_title>Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds</brief_title>
  <official_title>Interferon Alfa Sensitivity in HIV/HCV Coinfected Persons Before and After Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type
      specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/
      HCV (hepatitis C virus) coinfected persons before and after administration of HIV
      medications (antiretroviral therapy).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We plan to perform liver biopsy by microlaparoscopy on previously untreated HIV/HCV
      coinfected persons, then give them a dose of peginterferon alfa 2b. HCV and HIV kinetics
      will be studied. Afterward, HIV will be treated using antiretroviral therapy and the
      procedure will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>HCV RNA</measure>
    <time_frame>48 hours after interferon administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>HCV RNA 48 hours after a single dose of peginterferon alfa 2b 1.5 Î¼g/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV RNA</measure>
    <time_frame>Pre and post administration of HIV meds</time_frame>
    <safety_issue>No</safety_issue>
    <description>HIV quantatative viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISG</measure>
    <time_frame>Pre and post interferon administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>Interferon stimulated genes as assessed in liver tissue and PBMC.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV Infection</condition>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-HIV Agents</intervention_name>
    <description>Interferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications.</description>
    <other_name>PegIntron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>HIV medication, 400 mg twice daily by mouth</description>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine and tenofovir disoproxil fumarate</intervention_name>
    <description>HIV medication, combination pill, once per day by mouth</description>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult Human

          -  Able to provide written informed consent

          -  HIV antibody positive

          -  HIV viral load positive

          -  HIV treatment naive

          -  Hepatitis C antibody positive

          -  Hepatitis C viral load positive

          -  Hepatitis C treatment naive

          -  Approved to take HIV medications for minimum 9 months

          -  Willing to use contraception, Life expectancy greater than 2 years

        Exclusion Criteria:

          -  Significant opportunistic infections within 12 month

          -  Hepatitis B positive

          -  Evidence of liver cirrhosis

          -  Decompensated liver disease

          -  Chronic alcohol abuse

          -  Allergy to raltegravir, tenofovir, and/or emtricitabine

          -  Active or suspected malignancy

          -  Sarcoidosis

          -  Active TB

          -  Coronary artery disease

          -  Uncontrolled seizures

          -  Untreated thyroid disease

          -  Untreated diabetes

          -  Weight greater than 125 kg

          -  Severe depression or severe psychiatric disorder

          -  Ongoing alcohol or illicit drug use

          -  Pregnant, nursing, pr planning to become pregnant

          -  Allergy to interferon
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <lastchanged_date>April 6, 2015</lastchanged_date>
  <firstreceived_date>January 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>David Thomas</investigator_full_name>
    <investigator_title>Chief, Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>Acquired Immune Deficiency Syndrome Virus</keyword>
  <keyword>AIDS Virus</keyword>
  <keyword>Immunodeficiency Virus, Human</keyword>
  <keyword>Virus, Human Immunodeficiency</keyword>
  <keyword>Hepatitis C</keyword>
  <keyword>Hepatitis C, chronic</keyword>
  <keyword>Hepatitis C virus</keyword>
  <keyword>Hepatitis C antibodies</keyword>
  <keyword>Hepatitis C antigens</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-HIV Agents</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
